A paired, randomized, double-blind, placebo-controlled trial of EMLA cream (eutectic mixture of local anesthetics) for primary localized cutaneous amyloidosis.
Phase 3
- Conditions
- primary localized cutaneous amyloidosissymmetryboth legsprimary localized cutaneous amyloidosislichen amyloidosusEMLAtopical anestheticpruritusitch
- Registration Number
- TCTR20170928005
- Lead Sponsor
- none
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
18-60 years old
primary localized cutaneous amyloidosis at both legs
symmetry
Exclusion Criteria
1.previous laser within 3 months or use topical treatment within 1 month
2.other skin diseases
3.pregnancy or lactation
4.history of allergy to anesthesic agents or amide derivative
5.glucose-6-phosphatase defiency (G6PD)
6.using nitric oxide, sulfonamides, dapsone, metoclopramide, nitrofurantoin, beta-blockers drug
7.arrhythmia
8.immunodeficiency
9.psychiatric problem
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method pruritus 0 wk, 2 wk, 4 wk, 8 wk visual analog scale (VAS)
- Secondary Outcome Measures
Name Time Method volume of elevated lesion 0 wk, 2 wk, 4 wk, 8 wk Antera 3D